XML 73 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Equity (Details)
 1 Months Ended 6 Months Ended 12 Months Ended
Jul. 08, 2020
shares
May 03, 2019
Feb. 08, 2019
$ / shares
shares
Oct. 01, 2016
May 06, 2016
Feb. 08, 2016
shares
May 17, 2021
$ / shares
shares
Nov. 21, 2020
USD ($)
shares
Nov. 19, 2020
$ / shares
shares
Aug. 31, 2019
USD ($)
$ / shares
Jun. 30, 2019
USD ($)
shares
Feb. 28, 2017
Aug. 26, 2016
Mar. 21, 2016
$ / shares
shares
Feb. 17, 2016
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
shares
Jun. 29, 2021
shares
Oct. 30, 2020
$ / shares
Mar. 12, 2020
$ / shares
shares
May 09, 2018
$ / shares
Sep. 25, 2017
USD ($)
Equity (Details) [Line Items]                                              
Forward split ratio                           On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the “Forward Stock Split”) and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.                   
Common stock, par value (in Dollars per share) | $ / shares                           $ 0.001   $ 0.001 $ 0.001            
Common stock, authorized                           360,000,000   100,000,000 100,000,000            
Agreement, description         the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company’s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.             the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company’s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company’s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit). the Company issued 1,468,750 shares (“Shares”) of the Company’s Common Stock, par value $0.001 (the “Offering”) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.                    
Issuance of common shares, shares             1,111,112                                
Financial amendment, description   the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (“FINRA”). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company’s common stock were exchanged for 17,693,625 shares of the Company’s Common Stock.                                          
Common stock, shares issued                               24,470,526 24,420,526            
Consulting fees (in Dollars) | $                                   $ 4,514,800          
Stock subscription receivable (in Dollars) | $                               $ 2,708,880   $ 3,160,360          
Due to related parties (in Dollars) | $                               $ 315,676 $ 288,445            
Due to related parties consideration (in Dollars) | $                   $ 4,872,340                          
Common stock price per share (in Dollars per share) | $ / shares             $ 2.25     $ 7.00                          
Shares issued                 50,000                   6,000        
Shares per price (in Dollars per share) | $ / shares                 $ 5                     $ 2      
Warrant issued                 200,000                            
Exercise price (in Dollars per share) | $ / shares                 $ 2.25                            
Warrant term                 5 years                            
Issuance of common stock                               3,384,615              
Aggregate common stock shares                               915,856              
Kameyama [Member]                                              
Equity (Details) [Line Items]                                              
Issuance of common shares, shares               24,694                              
Unpaid consulting fees (in Dollars) | $               $ 49,388                              
Articles of Incorporation [Member]                                              
Equity (Details) [Line Items]                                              
Common stock, par value (in Dollars per share) | $ / shares                                         $ 0.001    
View Trade Securities Inc [Member]                                              
Equity (Details) [Line Items]                                              
Common stock, shares issued                                 60,000            
Consulting fees (in Dollars) | $                                 $ 135,000            
Placement agent agreement, description Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision.                                            
Restricted common shares 6,000                                            
Consulting Agreement [Member]                                              
Equity (Details) [Line Items]                                              
Common stock price per share (in Dollars per share) | $ / shares                                 $ 2.9            
Unrestricted common shares                                 50,000            
Non Related Parties [Member]                                              
Equity (Details) [Line Items]                                              
Debt conversion, description                               a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company’s common stock, and warrants to purchase 159,145 shares of the Company’s common stock.   b. Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company’s common stock, and warrants to purchase 154,368 shares of the Company’s common stock.     c. C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company’s common stock, and warrants to purchase 162,908 shares of the Company’s common stock.     d. KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company’s common stock, and warrants to purchase 126,530 shares of the Company’s common stock.     e. Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company’s common stock, and warrants to purchase 192,784 shares of the Company’s common stock.   f.KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company’s common stock, and warrants to purchase 120,121 shares of the Company’s common stock.              
Share Exchange Agreement [Member]                                              
Equity (Details) [Line Items]                                              
Common stock issued post-stock split           164,387,376                                  
Common stock issued pre-stock split           52,336,000                                  
Share Exchange Agreement One [Member]                                              
Equity (Details) [Line Items]                                              
Common stock issued post-stock split           166,273,921                                  
Common stock issued pre-stock split           52,936,583                                  
Share Exchange Agreement Two [Member]                                              
Equity (Details) [Line Items]                                              
Common stock issued post-stock split           163,159,952                                  
Common stock issued pre-stock split           51,945,225                                  
Percentage of common shares issued and outstanding           79.70%                                  
Percentage of issued share capital           100.00%                                  
Share Exchange Agreement Three [Member]                                              
Equity (Details) [Line Items]                                              
Common stock issued post-stock split           166,273,921                                  
Common stock issued pre-stock split           52,936,583                                  
Share Exchange Agreement Four [Member]                                              
Equity (Details) [Line Items]                                              
Common stock issued post-stock split           205,519,223                                  
Common stock issued pre-stock split           65,431,144                                  
Collaborative Arrangement [Member]                                              
Equity (Details) [Line Items]                                              
Issuance of common shares, shares                     428,571                        
Consulting agreement, description       On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s Common Stock at $1.00 per share for any amount exceeding $3,000.                                      
Issuance of common shares (in Dollars) | $                     $ 3,000,000                        
Euro-Asia Investment & Finance Corp Ltd. [Member]                                              
Equity (Details) [Line Items]                                              
Common stock, shares issued                                   644,972          
Co-Dev Agreement [Member]                                              
Equity (Details) [Line Items]                                              
Due to related parties (in Dollars) | $                                             $ 3,000,000
Consulting Agreement [Member]                                              
Equity (Details) [Line Items]                                              
Shares issued                                 521,887            
Private Placement [Member]                                              
Equity (Details) [Line Items]                                              
Aggregated capital contributions (in Dollars) | $                                 $ 7,615,331            
Number of investors                                 45            
Number of investors (in Dollars per share) | $ / shares                                 $ 2.25            
BioLite [Member]                                              
Equity (Details) [Line Items]                                              
Issuance of common shares, shares     74,997,546                                        
BioKey [Member]                                              
Equity (Details) [Line Items]                                              
Common stock issued post-stock split     1,642,291                                        
Issuance of common shares, shares     29,561,231                                        
Number of investors (in Dollars per share) | $ / shares     $ 1.50                                        
Minimum [Member]                                              
Equity (Details) [Line Items]                                              
Number of investors (in Dollars per share) | $ / shares                                           $ 2.00  
Minimum [Member] | Articles of Incorporation [Member]                                              
Equity (Details) [Line Items]                                              
Common stock, authorized                                         20,000,000    
Minimum [Member] | Consulting Agreement [Member]                                              
Equity (Details) [Line Items]                                              
PRice per share (in Dollars per share) | $ / shares                                 $ 2            
Maximum [Member] | Articles of Incorporation [Member]                                              
Equity (Details) [Line Items]                                              
Common stock, authorized                                         100,000,000    
Maximum [Member] | Consulting Agreement [Member]                                              
Equity (Details) [Line Items]                                              
SaleOfStockPricePerShare                                 3.68            
2016 Equity Incentive Plan [Member]                                              
Equity (Details) [Line Items]                                              
Common stock issued post-stock split                             157,050                
Common stock issued pre-stock split                             50,000